Treprostinil and Apixaban: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Apixaban
Treprostinil
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
These two medicines can both make bleeding more likely. Apixaban (Eliquis) is a blood thinner, and treprostinil (used for pulmonary hypertension) can make platelets less sticky, so blood clots a little less easily. Taken together, their effects add up, which can raise your chance of bleeding.
This concern is theoretical, meaning it is based on how the drugs work rather than lots of real-world cases. Watch for unusual bruising, nosebleeds, pink or red urine, black stools, or bleeding that will not stop. Report these right away, and go to the ER for serious bleeding. Keep taking both as prescribed, and your care team can manage this safely.
Additive bleeding risk (pharmacodynamic). Apixaban is a direct factor Xa inhibitor; treprostinil is a prostacyclin analog with antiplatelet activity. Combined, they impair hemostasis via complementary pathways, increasing bleeding risk. Neither is a prodrug; this is a PD, not PK, interaction.
- Direction: increased bleeding risk.
- Evidence: theoretical; onset unspecified.
- Severity: major.
- Management: monitor clinically for signs/symptoms of blood loss; educate patient. Apixaban's PD effect persists >=24h after last dose. In active pathological hemorrhage, discontinue apixaban; andexanet alfa reverses anti-FXa activity, or consider PCC/aPCC/rFVIIa. Note: PT/INR/aPTT and anti-FXa are not reliable to monitor reversal when PCCs are used.
What happens
Increased risk of bleeding and can cause serious, potentially fatal bleeding
Interaction Deep Dive
Using apixaban together with antiplatelet drugs raises the likelihood of bleeding1. In a patient receiving both anticoagulants and antiplatelet medications, any indications or symptoms of blood loss should be assessed without delay 2. Apixaban should be stopped in patients experiencing active pathological hemorrhage. Patients should be informed about the signs and symptoms of blood loss and instructed to report them right away or seek care at an emergency room. In cases of active pathological hemorrhage, discontinue apixaban. There is an agent available that reverses the anti-factor Xa activity of apixaban. Apixaban's pharmacodynamic effect is anticipated to remain for a minimum of 24 hours following the final dose. Options that may be considered include prothrombin complex concentrate (PCC), activated prothrombin complex concentrate, or recombinant factor VIIa. If PCCs are administered, it is neither helpful nor recommended to monitor apixaban's anticoagulant effect through a clotting test (PT, INR, or aPTT) or anti-factor Xa (FXa) activity. The absorption of apixaban is decreased by activated oral charcoal, which in turn reduces apixaban plasma concentration 1.
Why it happens (mechanism)
Additive effects on hemostasis
How to manage this interaction
The goal is to catch any bleeding early. Both drugs can be used together when your care team decides the benefit is worth it, but they will watch you more closely.
- Keep taking both medicines exactly as prescribed unless your prescriber tells you otherwise.
- Learn the warning signs: unusual bruising, nosebleeds, bleeding gums, red or dark urine, black or bloody stools, coughing or vomiting blood, or severe headache.
- Report bleeding right away, and go to an emergency room for serious or nonstop bleeding.
- Tell every provider and your pharmacist that you take both, and ask before starting anything new (including aspirin or NSAIDs).
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
3 reports — tap to read
a) A clinical study involving high-risk patients following acute coronary syndrome who were treated with aspirin or with aspirin plus clopidogrel (APPRAISE-2) was stopped early because bleeding occurred more frequently with apixaban than with placebo. Among patients on single antiplatelet therapy, the rate of ISTH major bleeding was 2.8% per year with apixaban compared with 0.6% per year with placebo, and among those on dual antiplatelet therapy it was 5.9% per year with apixaban versus 2.5% per year with placebo 1.
b) Among patients taking apixaban, the addition of aspirin raised the bleeding risk from 1.8% per year to 3.4% per year, and the addition of both aspirin and warfarin raised the bleeding risk from 2.7% per year to 4.6% per year in a clinical trial (ARISTOTLE); dual antiplatelet therapy was used with apixaban only to a limited extent (2.3%) in this trial 1.
c) In a retrospective study, combining a direct oral anticoagulant (DOAC) with antiplatelet therapy (APT; n=78) versus DOAC therapy alone (n=329) did not meaningfully change the rate of major bleeding (1.3% vs 1.2%) or of clinically relevant non-major bleeding (10.2% vs 6.4%) across 6 months of treatment. The patients were mainly Caucasian men with a mean age of 63.7 years. Compared with those on DOAC monotherapy, patients receiving concurrent APT had significantly higher mean body mass index (30.7 vs 28.4), higher mean CHA2DS2-VASc score (4.28 vs 3.85), and were more likely to have diabetes (26.9% vs 17.3%). DOACs were given for VTE treatment or atrial fibrillation and consisted of apixaban (58.5%), rivaroxaban (38.1%), and dabigatran (3.4%). Single antiplatelet therapy was used in 94.9% (74 patients), with aspirin 81 mg once daily being the most frequent regimen (69 patients). Additional APT regimens comprised aspirin 81 mg twice daily (3 patients), aspirin 325 mg daily (1 patient), clopidogrel 75 mg daily (1 patient), and dual APT with aspirin 81 mg and clopidogrel 75 mg daily (4 patients) 3.
Common questions
Can I take Treprostinil and Apixaban together?
Apixaban and treprostinil both raise bleeding risk, so watch closely for any unusual bleeding and report it promptly. Keep taking both as prescribed and let your care team monitor you. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Treprostinil and Apixaban interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Treprostinil and Apixaban interaction managed?
The goal is to catch any bleeding early. Both drugs can be used together when your care team decides the benefit is worth it, but they will watch you more closely. Keep taking both medicines exactly as prescribed unless your prescriber tells you otherwise. Learn the warning signs: unusual bruising, nosebleeds, bleeding gums, red or dark urine, black or bloody stools, coughing or vomiting blood, or… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Treprostinil or Apixaban need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: ELIQUIS(R) oral film coated tablets, apixaban oral film coated tablets. Bristol-Myers Squibb Company (per Dailymed), Princeton, NJ, 2024. DailyMed
- Product Information: SAVAYSA(R) oral tablets, edoxaban oral tablets. Daiichi Sankyo Inc (per FDA), Basking Ridge, NJ, 2023. DailyMed
- Tinkham TT, Vazquez SR, Jones AE, et al: Direct oral anticoagulant plus antiplatelet therapy: prescribing practices and bleeding outcomes. J Thromb Thrombolysis 2020; 49(3):492-496. PubMed
Keep reading about Apixaban
Keep reading about Treprostinil
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist